Related Experiment Video
Updated: Jul 30, 2026
Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat
Published on: February 7, 2011
Deciphering the Hypoglycemic Glucagon Response: Development of a Graded Hyperinsulinemic Hypoglycemic Clamp Technique
1Department of Clinical Sciences, Lund, Medicine, Lund University, SE-221 84 Lund, Sweden.
Abstract:
Glucose lowering therapy in type 1 and type 2 diabetes is often associated with hypoglycemic events. To avoid this, glucose lowering therapies need to be developed that support the hypoglycemic defense mechanisms. Such development needs a tool for evaluating counterregulatory mechanisms in vivo. A sustained glucagon release during hypoglycemia is of most importance to hypoglycemic defense mechanisms. We have therefore developed a graded hyperinsulinemic hypoglycemic clamp in mice and used it to evaluate counterregulatory glucagon dynamics. Glucose was clamped at narrow intervals aiming at 2.5, 3.5, 4.5, and 6.0 mmol/L. Glucagon levels were increased during hypoglycemia in a glucose-dependent way with a glucagon counterregulatory threshold between 3.5 and 4.0 mmol/L. Modelling the glucose-glucagon relationship using a hyperbolic curve with the equation: plasma glucagon = -4.20 + 90.79/blood glucose showed high correlation. When comparing this method to the insulin tolerance test as an approach to study glucagon dynamics in vivo, we found that the graded clamp more efficiently evoked a robust, predictable, glucagon response with considerably less variation in blood glucose. In conclusion, we have developed a tool for the study of in vivo glucagon dynamics during hypoglycemia in mice and demonstrated a hyperbolic glucose-counterregulatory glucagon relationship.
Insights
Developing new diabetes therapies requires understanding how the body defends against low blood sugar. This study introduces a new mouse model to effectively measure glucagon responses during hypoglycemia, crucial for improving glucose-lowering treatments.
Area of Science:
- Endocrinology
- Metabolic Research
- Animal Models
Background:
- Diabetes therapies can cause hypoglycemia, necessitating treatments that support natural defense mechanisms.
- Evaluating in vivo counterregulatory responses is vital for developing safer glucose-lowering drugs.
- Sustained glucagon release is a key component of the body's defense against hypoglycemia.
Purpose of the Study:
- To develop and validate a novel tool for assessing counterregulatory glucagon dynamics in vivo during hypoglycemia.
- To characterize the glucose-glucagon relationship during controlled hypoglycemia in a mouse model.
Main Methods:
- A graded hyperinsulinemic hypoglycemic clamp technique was established in mice.
- Glucose levels were precisely clamped at 2.5, 3.5, 4.5, and 6.0 mmol/L.
- Plasma glucagon levels were measured and modeled against blood glucose concentrations.
Main Results:
- Glucagon levels increased in a glucose-dependent manner during hypoglycemia.
- A glucagon counterregulatory threshold was identified between 3.5 and 4.0 mmol/L.
- A hyperbolic glucose-glucagon relationship was observed (plasma glucagon = -4.20 + 90.79/blood glucose) with high correlation.
- The graded clamp demonstrated a more robust and predictable glucagon response compared to the insulin tolerance test.
Conclusions:
- A validated graded hyperinsulinemic hypoglycemic clamp method effectively studies in vivo glucagon dynamics in mice.
- This tool aids in evaluating counterregulatory mechanisms essential for developing safer diabetes therapies.
- A hyperbolic relationship exists between glucose levels and counterregulatory glucagon release during hypoglycemia.
